Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis

Journal of Clinical Investigation

Volumn 103, Issue 2, 1999, Pages 281-290

  Howard, Laurence M ^a   Miga, Amy J ^b   Vanderlugt, Carol L ^a   Dal Canto, Mauro C ^a   Laman, Jon D ^c,d   Noelle, Randolph J ^b   Miller, Stephen D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GLYCOPROTEIN GP 39; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; MONOCLONAL ANTIBODY;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DEMYELINATING DISEASE; EFFECTOR CELL; FEMALE; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RELAPSE; T LYMPHOCYTE;

EID: 0032953939     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI5388     Document Type: Article

References (44)

1. Brown, A.M., and McFarlin, D.E. 1981. Relapsing experimental allergic encephalomyelitis in the SJL/J mouse. Lab. Invest. 45:278-284.
2. McRae, B.L., Kennedy, M.K., Tan, L.J., Dal Canto, M.C., and Miller, S.D. 1992. Induction of active and adoptive chronic-relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J. Neuroimmunol. 38:229-240.
3. Lehmann, P.V., Sercarz, E.E., Forsthuber, T., Dayan, C.M., and Gammon, G. 1993. Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol. Today. 14:203-208.
4. McRae, B.L., Vanderlugt, C.L., Dal Canto, M.C., and Miller, S.D. 1995. Functional evidence for epitope spreading in the relapsing pathology of EAE in the SJL/J mouse. J. Exp. Med. 182:75-85.
5. Vanderlugt, C.L., and Miller, S.D. 1996. Epitope spreading. Curr. Opin. Immunol. 8:831-836.
6. Vanderlugt, C.L., Karandikar, N.J., Bluestone, J.A., and Miller, S.D. 1998. The functional significance of epitope spreading and its regulation by costimulatory interactions. Immunol. Rev. 164:63-72.
7. Kennedy, M.K., et al. 1990. Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides. J. Immunol. 144:909-915.
8. Kennedy, M.K., Tan, L.J., Dal Canto, M.C., and Miller, S.D. 1990. Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. J. Immunol. 145:117-126.
9. Santambrogio, L., et al. 1995. Tolerogenic forms of auto-antigens and cytokines in the induction of resistance to experimental allergic encephalomyelitis. J. Neuroimmunol. 58:211-222.
10. Karpus, W.J., Pope, J.G., Peterson, J.D., Dal Canto, M.C., and Miller, S.D. 1995. Inhibition of Theiler's virus-mediated demyelination by peripheral immune tolerance induction. J. Immunol. 155:947-957.
11. Kuchroo, V.K., et al. 1995. B7-1 and B7-2 costimulatory molecules differentially activate the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 80:707-718.
12. Perrin, P.J., et al. 1995. Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. J. Immunol. 154:1481-1490.
13. Miller, S.D., et al. 1995. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity. 3:739-745.
14. Grewal, I.S., et al. 1996. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science. 273:1864-1867.
15. Gerritse, K., et al. 1996. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. USA. 93:2499-2504.
16. Griggs, N.D., et al. 1996. The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expansion and pathogenic acquisition of self-reactive T cells. J. Exp. Med. 183:801-810.
17. Carayanniotis, G., Masters, S.R., and Noelle, R.J. 1997. Suppression of murine thyroiditis via blockade of the CD40-CD40L interaction. Immunology. 90:421-426.
18. Mohan, C., Shi, Y., Laman, J.D., and Datta, S.K. 1995. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J. Immunol. 154:1470-1480.
19. Durie, F.H., et al. 1993. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science. 261:1328-1330.
20. Balasa, B., et al. 1997. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J. Immunol. 159:4620-4627.
21. Mach, F., Schonbeck, U., Sukhova, G.K., Atkinson, E., and Libby, P. 1998. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 394:200-203.
22. Stout, R.D., and Suttles, J. 1996. The many roles of CD40 in cell-mediated inflammatory responses. Immunol. Today. 17:487-492.
23. Schultze, J.L., et al. 1997. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J. Clin. Invest. 100:2757-2765.
24. Van Kooten, C., and Banchereau, J. 1996. CD40-CD40 ligand: a multi-functional receptor-ligand pair. Adv. Immunol. 61:1-77.
25. Grewal, I.S., and Flavell, R.A. 1996. A central role of CD40 ligand in the regulation of CD4+ T-cell responses. Immunol. Today. 17:410-414.
26. Kelsall, B.L., Stuber, E., Neurath, M., and Strober, W. 1996. Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T-cell responses. Ann. NY Acad. Sci. 795:116-126.
27. Dal Canto, M.C., and Lipton, H.L. 1975. Primary demyelination in Theiler's virus infection. An ultrastructural study. Lab. Invest. 33:626-637.
28. Scuber, E., Strober, W., and Neurath, M. 1996. Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J. Exp. Med. 183:693-698.
29. Laman, J.D., Claassen, E., and Noelle, R.J. 1996. Functions of CD40 and its ligand, gp39 (CD40L). Crit. Rev. Immunol. 16:59-108.
30. Hancock, W.W., et al. 1996. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc. Natl. Acad. Sci. USA. 93:13967-13972.
31. Early, G.S., Zhao, W., and Burns, C.M. 1996. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J. Immunol. 157:3159-3164.
32. Hollenbaugh, D., et al. 1995. Expression of functional CD40 by vascular endothelial cells. J. Exp. Med. 182:33-40.
33. Dechanet, J., et al. 1997. CD40 ligand stimulates proinflammatory cytokine production by human endothelial cells. J. Immunol. 159:5640-5647.
34. Stout, R.D., Suttles, J., Xu, J., Grewal, I.S., and Flavell, R.A. 1996. Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. J. Immunol. 156:8-11.
35. Malik, N., Greenfield, B.W., Wahl, A.F., and Kiener, P.A. 1996. Activation of human monocytes through CD40 induces matrix metalloproteinases. J. Immunol. 156:3952-3960.
36. Tian, L., Noelle, R.J., and Lawrence, D.A. 1995. Activated T cells enhance nitric oxide production by murine splenic macrophages through gp39 and LFA-1. Eur. J. Immunol. 25:306-309.
37. Karandikar, N.J., et al. 1998. Tissue-specific up-regulation of B7-1 expression and function during the course of murine relapsing experimental autoimmune encephalomyelitis. J. Immunol. 161:192-199.
38. Ranheim, E.A., and Kipps, T.J. 1993. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J. Exp. Med. 177:925-935.
39. Grewal, I.S., Xu, J., and Flavell, R.A. 1995. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature. 378:617-620.
40. Shu, U., et al. 1995. Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction. Eur. J. Immunol. 25:1125-1128.
41. Cella, M., et al. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:747-752.
42. Garside, P., et al. 1998. Visualization of specific B and T lymphocyte interactions in the lymph node. Science. 281:96-99.
43. Samoilova, E.B., Horton, J.L., Zhang, H.D., and Chen, Y.H. 1997. CD40L blockade prevents autoimmune encephalomyelitis and hampers TH1 but not TH2 pathway of T cell differentiation. J. Mol. Med. 75:603-608.
44. Racke, M.K., et al. 1994. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 180:1961-1966.